European Society for Medical Oncology Advanced Course on Early Drug Development Singapore 2023
Format: 14 videos + 15 pdfs, size: 1.54 GB
Course Audience: oncologist
Overview:
- Start date: 24 Feb 2023
- End date: 25 Feb 2023
- Location: Singapore, Republic of Singapore
Learning objectives
- To foster, educate and mentor the next generation of Phase I/Early Drug Development Programmes in Oncology centres from both the established and emerging economies in the Asia-Pacific region.
- To understand the fundamentals of establishing and running a successful Phase I/Early Drug Development Programme: from an in-depth understanding of trial selection to patient coordination, to running a programme, to effectively engaging with sponsors and fellow PIs, to regional and international engagement, and regulatory processes.
- To bridge the gap between the key stakeholders in the drug development process in the Asia-Pacific region: investigators, sponsors (Pharma and Biotech), Contract Research Organization (CRO), regulatory bodies.
ESMO-Advanced-Course-on-Early-Drug-Development-2023-Programme (PDF Format)
Session 1 Current designs of Phase 1 clinical trials (Video MP4 Format)Session 1 Current designs of Phase 1 clinical trials (PDF Format)Session 1 Importance of Phase I trials in drug development Historical perspective (Video MP4 Format)Session 1 Importance of Phase I trials in drug development Historical perspective (PDF Format)Session 1 Limitation of current designs and future designs (Video MP4 Format)Session 1 Limitation of current designs and future designs (PDF Format)Session 2 Immunotherapy, biomarkers, combinational approach (Video MP4 Format)Session 2 Immunotherapy, biomarkers, combinational approach (PDF Format)Session 2 Other agents e.g. drug conjugates, hormonal agents, cell-based therapies,. (Video MP4 Format)Session 2 Other agents e.g. drug conjugates, hormonal agents, cell-based therapies,. (PDF Format)Session 2 Targeted therapy, biomarkers, combinatorial approach (Video MP4 Format)Session 2 Targeted therapy, biomarkers, combinatorial approach (PDF Format)Session 3 Assessing efficacy in novel Phase I trials (Video MP4 Format)Session 3 Assessing efficacy in novel Phase I trials (PDF Format)Session 3 Ethnic differences in drug tolerance and response (Video MP4 Format)Session 3 Ethnic differences in drug tolerance and response (PDF Format)Session 3 Patient selection Genomic matching to Phase I trials, NGS, ctDNA, existing programmes (Video MP4 Format)Session 3 Patient selection Genomic matching to Phase I trials, NGS, ctDNA, existing programmes (PDF Format)Session 3 Safety and adverse events management (Video MP4 Format)Session 3 Safety and adverse events management (PDF Format)Session 4 Challenges Facing Covid-19 and lessons learnt (Video MP4 Format)Session 4 Challenges Facing Covid-19 and lessons learnt (PDF Format)Session 4 Industry’s perspective Challenges, how to assess a site, metrics (Video MP4 Format)Session 4 Industry’s perspective Challenges, how to assess a site, metrics (PDF Format)Session 4 Principal investigator’s perspective Assessing protocol, logistics, budget, resource allocation (Video MP4 Format)Session 4 Principal investigator’s perspective Assessing protocol, logistics, budget, resource allocation (PDF Format)Welcome and course overview (Video MP4 Format)Welcome and course overview (PDF Format)